Sun Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their investigational drug, deuruxolitinib. This oral selective inhibitor of Janus kinases JAK1 and JAK2 seeks to offer relief to adults grappling with moderate to severe alopecia areata. With an 8mg twice-daily regimen, Sun […]
Sun Pharma Canada, a subsidiary of Sun Pharmaceutical Industries, has secured Health Canada’s approval for their pioneering acne treatment, WINLEVI (clascoterone cream 1%). This marks the first approval of an androgen receptor inhibitor for topical treatment of acne vulgaris in patients aged 12 and older, presenting a groundbreaking advancement in acne treatments for Canadian patients […]
India-based Sun Pharmaceutical Industries (Sun Pharma) will acquire US-based Concert Pharmaceuticals for equity consideration of $576 million to strengthen its global dermatology franchise. Concert Pharmaceuticals is developing deuruxolitinib, a novel, deuterated, oral Janus kinases JAK1/2 inhibitor for the treatment of Alopecia Areata, an autoimmune dermatological disease resulting in partial or complete loss of hair on […]
Sun Pharmaceutical Industries has secured approval for SEZABY (phenobarbital sodium powder for injection) from the US Food and Drug Administration (FDA) for the treatment of neonatal seizures. According to Sun Pharmaceutical, the approval makes SEZABY the first and only product to be indicated specifically in the US for treating neonatal seizures in term and preterm […]
Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for CEQUA (cyclosporine ophthalmic solution) 0.09%, a significant advancement in the treatment of keratoconjunctivitis sicca, commonly known as dry eye disease. This approval introduces a new therapeutic option for a condition that affects millions worldwide, addressing a substantial unmet medical […]